We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Anti-SARS-CoV-2 Drug Candidate Enters Phase 1 Trial in the US

Anti-SARS-CoV-2 Drug Candidate Enters Phase 1 Trial in the US

Anti-SARS-CoV-2 Drug Candidate Enters Phase 1 Trial in the US

Anti-SARS-CoV-2 Drug Candidate Enters Phase 1 Trial in the US

Credit: Shaun F/ Pixabay
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Anti-SARS-CoV-2 Drug Candidate Enters Phase 1 Trial in the US"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.

DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.

Researchers found that DC402234 exhibits effective inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 0.053 ± 0.005 μM, and vibrant anti-SARS-CoV-2-infection activity in cell culture (EC50 values of 0.42 ± 0.08 μM).

Furthermore, DC402234 shows good pharmacokinetic properties and safety in vivo.

Prof. Gregory Tarcey, main investigator of DC402234 from the US Frontage Phase I Research Center, will carry out the Phase I clinical trial in the United States.

The study was led by Professors LIU Hong, XU Yechun and JIANG Hualiang’s teams from SIMM, together with Professors YANG Haitao, RAO Zihe’s team from Shanghai Institute for Advanced Immunochemical Studies of ShanghaiTech University, and Professors ZHANG Lei-Ke, XIAO Gengfu’s team from Wuhan Institute of Virology of CAS.

The effective anti-SARS-CoV-2 in vitro activity of DC402234 will bring more research prospects. However, there is still a long way to go for DC402234 as a new drug, from entering the human clinical trial stage to final application and marketing in the future.

Reference: Dai W, Zhang B, Jiang X-M, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331-1335. doi: 10.1126/science.abb4489

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.